Richard Kraemer1,2, Hans-Jürgen Smith3, Fabian Gardin4, Jürg Barandun4, Stefan Minder3, Lukas Kern5, Martin H Brutsche5. 1. Center of Pulmonary Medicine, Hirslanden Private Hospital Group, Salem-Hospital, Bern, Switzerland. 2. Department of Biomedical Research, University of Bern, Bern, Switzerland. 3. Medical Development, Research in Respiratory Diagnostics, Berlin, Germany. 4. Center of Pulmonary Medicine, Hirslanden Private Hospital Group, Clinic Hirslanden, Zürich, Switzerland. 5. Clinic of Pneumology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
Abstract
BACKGROUND: Airflow reversibility criteria in COPD are still debated - especially in situations of co-existing COPD and asthma. Bronchodilator response (BDR) is usually assessed by spirometric parameters. Changes assessed by plethysmographic parameters such as the effective, specific airway conductance (sGeff), and changes in end-expiratory resting level at functional residual capacity (FRCpleth) are rarely appreciated. We aimed to assess BDR by spirometric and concomitantly measured plethysmographic parameters. Moreover, BDR on the specific aerodynamic work of breathing (sWOB) was evaluated. METHODS: From databases of 3 pulmonary centers, BDR to 200 g salbutamol was retrospectively evaluated by spirometric (∆FEV1 and ∆FEF25-75), and plethysmographic (∆sGeff, ∆FRCpleth, and ∆sWOB) parameters in a total of 843 patients diagnosed as COPD (478 = 57%), asthma-COPD-overlap (ACO) (139 = 17%), or asthma (226 = 27%), encountering 1686 BDR-measurement-sets (COPD n = 958; ACO n = 276; asthma n = 452). RESULTS: Evaluating z-score improvement taking into consideration the whole pre-test z-score range, highest BDR was achieved by combining ∆sGeff and ∆FRC detecting BDR in 62.2% (asthma: 71.4%; ACO: 56.7%; COPD: 59.8%), by ∆sGeff in 53.4% (asthma: 69.1%; ACO: 51.6%; COPD: 47.4%), whereas ∆FEV1 only distinguished in 10.6% (asthma: 21.8%; ACO: 18.6%; COPD: 4.2%). Remarkably, ∆sWOB detected BDR in 49.4% (asthma: 76.2%; ACO: 47.8%; COPD: 46.9%). CONCLUSION: BDR largely depends on the pre-test functional severity and, therefore, should be evaluated in relation to the pre-test conditions expressed as ∆z-scores, considering changes in airway dynamics, changes in static lung volumes and changes in small airway function. Plethysmographic parameters demonstrated BDR at a significant higher rate than spirometric parameters.
BACKGROUND: Airflow reversibility criteria in COPD are still debated - especially in situations of co-existing COPD and asthma. Bronchodilator response (BDR) is usually assessed by spirometric parameters. Changes assessed by plethysmographic parameters such as the effective, specific airway conductance (sGeff), and changes in end-expiratory resting level at functional residual capacity (FRCpleth) are rarely appreciated. We aimed to assess BDR by spirometric and concomitantly measured plethysmographic parameters. Moreover, BDR on the specific aerodynamic work of breathing (sWOB) was evaluated. METHODS: From databases of 3 pulmonary centers, BDR to 200 g salbutamol was retrospectively evaluated by spirometric (∆FEV1 and ∆FEF25-75), and plethysmographic (∆sGeff, ∆FRCpleth, and ∆sWOB) parameters in a total of 843 patients diagnosed as COPD (478 = 57%), asthma-COPD-overlap (ACO) (139 = 17%), or asthma (226 = 27%), encountering 1686 BDR-measurement-sets (COPD n = 958; ACO n = 276; asthma n = 452). RESULTS: Evaluating z-score improvement taking into consideration the whole pre-test z-score range, highest BDR was achieved by combining ∆sGeff and ∆FRC detecting BDR in 62.2% (asthma: 71.4%; ACO: 56.7%; COPD: 59.8%), by ∆sGeff in 53.4% (asthma: 69.1%; ACO: 51.6%; COPD: 47.4%), whereas ∆FEV1 only distinguished in 10.6% (asthma: 21.8%; ACO: 18.6%; COPD: 4.2%). Remarkably, ∆sWOB detected BDR in 49.4% (asthma: 76.2%; ACO: 47.8%; COPD: 46.9%). CONCLUSION: BDR largely depends on the pre-test functional severity and, therefore, should be evaluated in relation to the pre-test conditions expressed as ∆z-scores, considering changes in airway dynamics, changes in static lung volumes and changes in small airway function. Plethysmographic parameters demonstrated BDR at a significant higher rate than spirometric parameters.
Keywords:
ACO; COPD; COPD and coexisting asthma; aerodynamic work of breathing; bronchodilator response; pulmonary hyperinflation; small airways dysfunction
Authors: P H Quanjer; P L Enright; M R Miller; J Stocks; G Ruppel; M P Swanney; R O Crapo; O F Pedersen; E Falaschetti; J P Schouten; R L Jensen Journal: Eur Respir J Date: 2011-03 Impact factor: 16.671
Authors: P S Bakke; E Rönmark; T Eagan; F Pistelli; I Annesi-Maesano; M Maly; M Meren; P Vermeire Dagger; J Vestbo; G Viegi; J Zielinski; B Lundbäck Journal: Eur Respir J Date: 2011-12 Impact factor: 16.671
Authors: Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri Journal: Am J Respir Crit Care Med Date: 2006-09-07 Impact factor: 21.405
Authors: Surya P Bhatt; Xavier Soler; Xin Wang; Susan Murray; Antonio R Anzueto; Terri H Beaty; Aladin M Boriek; Richard Casaburi; Gerard J Criner; Alejandro A Diaz; Mark T Dransfield; Douglas Curran-Everett; Craig J Galbán; Eric A Hoffman; James C Hogg; Ella A Kazerooni; Victor Kim; Gregory L Kinney; Amir Lagstein; David A Lynch; Barry J Make; Fernando J Martinez; Joe W Ramsdell; Rishindra Reddy; Brian D Ross; Harry B Rossiter; Robert M Steiner; Matthew J Strand; Edwin J R van Beek; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Robert A Wise; Edwin K Silverman; James D Crapo; Russell P Bowler; MeiLan K Han Journal: Am J Respir Crit Care Med Date: 2016-07-15 Impact factor: 21.405
Authors: Paul Albert; Alvar Agusti; Lisa Edwards; Ruth Tal-Singer; Julie Yates; Per Bakke; Bartolome R Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William Macnee; Bruce Miller; Stephen Rennard; Edwin K Silverman; Jørgen Vestbo; Emiel Wouters; Peter Calverley Journal: Thorax Date: 2012-06-13 Impact factor: 9.139
Authors: Sandeep Bodduluri; Abhilash Kizhakke Puliyakote; Arie Nakhmani; Jean-Paul Charbonnier; Joseph M Reinhardt; Surya P Bhatt Journal: Am J Respir Crit Care Med Date: 2021-01-15 Impact factor: 21.405